Clovis Oncology Inc. (NASDAQ:CLVS) went down by -8.94% from its latest closing price compared to the recent 1-year high of $4.91. The company’s stock price has collected -24.83% of loss in the last five trading sessions.
Is It Worth Investing in Clovis Oncology Inc. (NASDAQ :CLVS) Right Now?
Plus, the 36-month beta value for CLVS is at 0.49. Opinions of the stock are interesting as 0 analysts out of 3 who provided ratings for Clovis Oncology Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $2.00, which is $0.88 above the current price. CLVS currently public float of 142.40M and currently shorts hold a 20.36% ratio of that float. Today, the average trading volume of CLVS was 11.06M shares.
CLVS’s Market Performance
CLVS stocks went down by -24.83% for the week, with a monthly drop of -17.65% and a quarterly performance of -31.71%, while its annual performance rate touched -75.49%. The volatility ratio for the week stands at 9.10% while the volatility levels for the past 30 days are set at 9.00% for Clovis Oncology Inc. The simple moving average for the period of the last 20 days is -9.24% for CLVS stocks with a simple moving average of -38.50% for the last 200 days.
Analysts’ Opinion of CLVS
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CLVS reach a price target of $33, previously predicting the price at $29. The rating they have provided for CLVS stocks is “Buy” according to the report published on May 18th, 2020.
SVB Leerink gave a rating of “Underperform” to CLVS, setting the target price at $5 in the report published on April 27th of the previous year.
CLVS Trading at -27.44% from the 50-Day Moving Average
After a stumble in the market that brought CLVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.19% of loss for the given period.
Volatility was left at 9.00%, however, over the last 30 days, the volatility rate increased by 9.10%, as shares sank -9.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.21% lower at present.
During the last 5 trading sessions, CLVS fell by -24.83%, which changed the moving average for the period of 200-days by -63.99% in comparison to the 20-day moving average, which settled at $1.2280. In addition, Clovis Oncology Inc. saw -58.67% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CLVS starting from MUEHL DANIEL W, who sale 2,234 shares at the price of $1.20 back on Sep 02. After this action, MUEHL DANIEL W now owns 99,161 shares of Clovis Oncology Inc., valued at $2,681 using the latest closing price.
IVERS-READ GILLIAN C, the of Clovis Oncology Inc., sale 2,234 shares at $1.20 during a trade that took place back on Sep 02, which means that IVERS-READ GILLIAN C is holding 288,919 shares at $2,681 based on the most recent closing price.
Stock Fundamentals for CLVS
Current profitability levels for the company are sitting at:
- -148.09 for the present operating margin
- +73.90 for the gross margin
The net margin for Clovis Oncology Inc. stands at -177.82. Equity return is now at value 89.60, with -57.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.